Aniracetam for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Aniracetam for Health & Longevity

Created on 09/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A fat-soluble laboratory-made compound that holds the brain's fast excitatory signalling open a little longer. Trials in older adults with diagnosed memory disorders point in opposite directions; healthy adults going about ordinary life have never been tested. Supply is the larger hazard — labels are often wrong. For an already healthy brain, the evidence base is close to empty. (Full Review)

Protocol

Standard clinical protocol
1,500 mg daily by mouth
Split into two or three doses with meals, for a minimum of four months. Alternative lower-dose protocol: 400–750 mg once or twice daily with food.
Best time of day
Morning and early afternoon
The compound prolongs excitatory signalling, so late dosing has no supporting rationale.
Taken with dietary fat
With a fat-containing meal
Fat-soluble and poorly absorbed fasted; the single largest controllable determinant of exposure.
Time to effect
Cognitive and behavioural symptoms
2–6 months
The trials that found benefit measured it at two to six months, not in days.
Emotional state
3 months
Emotional state improved at three months in open-label data, the endpoint that moved earliest.
Cognitive and functional stability
6–12 months
Neuropsychological parameters held steady at 6 and 12 months without randomisation or a placebo group.

Benefits

Contraindications
  • Epilepsy or a prior unprovoked seizure, or taking perampanel
  • Pregnancy and breastfeeding
  • Severe hepatic impairment (Child-Pugh Class C)
  • Severe renal impairment (creatinine clearance below 30 mL/min)
  • Moderate-to-severe dementia (Mini-Mental State Examination below 15)
  • Anyone under 18
    •
Key Interactions
  • Sedative-hypnotics (zopiclone, zolpidem, benzodiazepines)
  • Cholinesterase inhibitors (donepezil, rivastigmine, galantamine)
  • Centrally acting pain medications (morphine, tramadol, and related agents)
  • Over-the-counter caffeine products (caffeine tablets, energy formulations)
  • Over-the-counter sedating antihistamines (diphenhydramine, doxylamine)
  • Other racetams and glutamate-modulating supplements (piracetam, oxiracetam)
  • Choline donors (citicoline, choline bitartrate)
    •

Risk & Side Effects

  • Medium: Confusion and agitation in older adults with dementia
    •
  • Low: Gastrointestinal upset, headache, and restlessness; exposure to undeclared and inaccurate doses in consumer products
  • Speculative: Lowered seizure threshold; blunting of pain relief from centrally acting medications; late-day activation and disrupted sleep; unknown consequences of sustained glutamate potentiation

Monitoring

Marker Target Why
Montreal Cognitive Assessment (MoCA) score 26–30 of 30 Objective anchor for any claimed cognitive change
ALT 10–26 U/L Confirms the only clearance pathway is intact
AST 10–26 U/L Cross-checks liver signal and flags muscle origin
eGFR 90 mL/min/1.73 m² or above Metabolite half-life lengthens 4- to 7-fold as filtration falls
Vitamin B12 500–900 pg/mL Excludes a reversible cause of memory complaints
TSH 0.5–2.0 mIU/L Excludes thyroid-driven cognitive slowing

Cadence: Liver enzymes, kidney filtration, vitamin B12, thyroid-stimulating hormone and a validated cognitive scale before the first dose; repeat the cognitive scale and liver enzymes at 12 weeks, then every six months, with eGFR annually.

Qualitative Assessment

  • Word-finding fluency in unrehearsed conversation
  • Time to settle into focused work at the start of a session
  • Emotional evenness under ordinary provocation
  • Sleep onset latency and number of night awakenings
  • Absence of new confusion, agitation, or muscle twitching
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.